Hormonal
Adherence to a high-carbohydrate diet (60% energy) for 14-20 weeks significantly increases regional cerebral blood flow in the nucleus accumbens (reward) and hypothalamus (homeostasis) compared to a low-carbohydrate diet (20% energy), suggesting neural mechanisms that may impede weight-loss maintenance.
If you are trying to maintain weight loss, the type of carbohydrates you eat matters for your brain's reward system. A diet high in carbohydrates (60% of calories) was shown to increase blood flow to the brain's reward and hunger centers compared to a low-carb diet (20% of calories). This neural activation may make it harder to stick to your diet long-term, even if you are eating the same number of calories. Consider reducing carbohydrate intake to lower levels to potentially dampen these reward-driven hunger signals.
We report significant differences in rCBF in adults assigned to diets varying in carbohydrate content for several months, which appear to be partially associated with insulin secretion. These findings suggest that chronic intake of a high-carbohydrate diet may affect brain reward and homeostatic activity in ways that could impede weight-loss maintenance.
Why this rating
Randomized controlled feeding trial with objective neuroimaging (pASL) and statistical correction, though subjective behavioral outcomes (hunger/cravings) did not differ.
Source
Diets Varying in Carbohydrate Content Differentially Alter Brain Activity in Homeostatic and Reward Regions in Adults
Laura M. Holsen et al. · Journal of Nutrition · 2021
DOI 10.1093/jn/nxab090
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →